HCR Wealth Advisors Sells 7,645 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

HCR Wealth Advisors lowered its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 71.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,061 shares of the financial services provider’s stock after selling 7,645 shares during the quarter. HCR Wealth Advisors’ holdings in iShares Biotechnology ETF were worth $405,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Darwin Wealth Management LLC acquired a new position in iShares Biotechnology ETF during the 3rd quarter worth approximately $29,000. Highline Wealth Partners LLC bought a new stake in shares of iShares Biotechnology ETF during the third quarter worth $30,000. Ashton Thomas Securities LLC acquired a new position in shares of iShares Biotechnology ETF during the third quarter worth $36,000. Modus Advisors LLC bought a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at $41,000. Finally, Voisard Asset Management Group Inc. acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter valued at $59,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of IBB stock opened at $133.42 on Thursday. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57. The stock’s fifty day simple moving average is $137.51 and its 200 day simple moving average is $141.93.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were issued a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.